Detail akcie Viridian Therapt Rg online

Business Summary: Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Viridian Therapeutics Inc revenues increased from $230K to $70.7M. Net loss increased 17% to $222.2M. Revenues reflect Collaboration revenue - related party increase from $230K to $717K. Higher net loss reflects Biopharmaceutical segment loss increase of 14% to $240.6M, United States segment loss increase of 14% to $240.6M.